Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DELIGHT: Dapagliflozin and Saxagliptin in T2D with CKD
NCT02547935Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2015
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of dapagliflozin, saxagliptin in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), sponsored by AstraZeneca. Started Sep 2015; status: completed.
02
Drugs
dapagliflozinsaxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02547935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02547935.